|
|
Novel MYBPC1 mutations cosegregate with a myopathy associated with muscle weakness, hypotonia and tremor |
| 5R01AR076373-03 |
|
NIAMS |
2022 |
|
|
Central Sensitization and Sleep Disturbance as Predictors of Treatment Outcomes in Patients with Knee Osteoarthritis |
| 5R01AR079792-02 |
|
NIAMS |
2022 |
|
|
Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities |
| 1K99DA056288-01 |
|
NIDA |
2022 |
|
|
Deep Brain Stimulation (DBS) For Severe Treatment Refractory Methamphetamine Use Disorder |
| 1UG3DA054746-01A1 |
|
NIDA |
2022 |
|
|
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse |
| 2R01DA041931-07A1 |
|
NIDA |
2022 |
|
|
Neural circuitry mediating behavioral flexibility |
| 3R00DA042934-05S2 |
|
NIDA |
2022 |
|
|
Methamphetamine Effects on Prefrontal Cortical PV+ Interneurons and Resulting Cognitive Deficits |
| 3R01DA054589-02S1 |
|
NIDA |
2022 |
|
|
Facilitating supervised self-management of stimulant medications among adolescents: improving adherence, reducing stigma, and supporting caregivers |
| 3R43DA053121-01A1S1 |
|
NIDA |
2022 |
|
|
Role of ARX mutations in marmoset brain organoids |
| 3U01DA054170-02S1 |
|
NIDA |
2022 |
|
|
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder |
| 4UH3DA047714-03 |
|
NIDA |
2022 |